

30 October 2015

TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2014/15 Invitation to Tender, dated 6 November 2014.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2014/15 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2018

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Bimatoprost	Eye drops 0.03%; 3 ml OP dropper bottle	\$18.50	\$3.65	Bimatoprost Actavis (Actavis)	1 April 2016	1 June 2016	1 September 2016	Lumigan (Allergan A&NZ)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Pack Price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Bimatoprost	Eye drops 0.03%; 3 ml dropper bottle	\$3.65	Bimatoprost Actavis (Actavis)	1%	1 April 2016	1 June 2016
Ketamine	Inj 100 mg per ml, 2 ml ampoule; 5 ampoules	\$47.05	Ketamine-Claris (AFT)	1%	1 March 2016	1 May 2016

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2013/14 Invitation to Tender, dated 7 November 2013, and the 2014/15 Invitation to Tender, dated 6 November 2014:

2013/14 Invitation to Tender

Chemical Name	Line Item
Ciprofloxacin	Eye drops 0.3%

2014/15 Invitation to Tender

Chemical Name	Line Item	Chemical Name	Line Item
Baclofen	Inj 2 mg per ml, 5 ml	Nitrofurantoin	Tab 50 mg
Chloramphenicol	Eye oint 1%	Nitrofurantoin	Tab 100 mg
Clonazepam	Tab 500 mcg	Nitrofurantoin	Tab modified release 50 mg
Clonazepam	Tab 2 mg	Nitrofurantoin	Tab modified release 100 mg
Dipyridamole	Tab long-acting 150 mg	Oestradiol	TDDS 25 mcg per day
Eptifibatide	Inj 0.75 mg per ml, 100 ml	Oestradiol	TDDS 50 mcg per day
Eptifibatide	Inj 2 mg per ml, 10 ml	Oestradiol	TDDS 75 mcg per day
Fludarabine phosphate	Inj 50 mg	Oestradiol	TDDS 100 mcg per day

For products included in the 2014/15 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.